SWEDENCARE

Year-end report

January - December 2025

Our vision

To establish ourselves as one of the leading companies within Pet Health Care within all larger markets

Swedencare AB (publ) | Org.nr 556470-3790

Note: The English version is a non-official translation of the original Swedish report.

This is Swedencare

Swedencare is listed on the NASDAQ First North Growth Market and also trades on the OTCQX® Best Market. We develop, produce, and sell premium products in the global and rapidly growing pet healthcare market, focusing on cats, dogs, and horses. Our extensive product portfolio includes strong brands such as **NaturVet®, Innovet, Pet MD®, Rx Vitamins®, nutravet®, Rileys®,** and **ProDen PlaqueOff®,** the original solution for good oral health.

With headquarters in Malmö, our products are sold in approximately 70 countries through online channels, pet stores, veterinarians, and FDMC. Our extensive distribution network consists of subsidiaries in nine countries, along with an international network of retailers. Swedencare has experienced strong growth for several years while maintaining high profitability.

Vision

Swedencare is established in all major markets as an innovative and reliable pet healthcare company. With a global presence and channel strategy as well as a broad portfolio of well-functioning Pet Health Care products for the most important therapy areas, it is **our vision to establish ourselves as one of the leading companies within Pet Health Care on all larger markets.**

Financial objective

- Annual double-digit organic growth
- Establish an Op. EBITDA margin above 26% midterm (approx. 23% Op. EBIT)
- Net debt/R12 Op. EBITDA (proforma and adjusted for IFRS16) ratio below 2.0*

These targets underscore Swedencare's focus on disciplined financial management, operational efficiency, and strategic expansion.
**Subject to flexibility for acquisitions.*

Dividend

Swedencare will propose a dividend that takes into account the group's profit as well as its consolidation and investment needs, liquidity, and financial position. The aim is to distribute a dividend equivalent to 40 percent of the profit after tax, adjusted for non-operating costs.

For 2025, the board proposes a dividend of 0.28 SEK (0.25 SEK) per share.

Mission

We care about improving the health and wellbeing of pets,
creating reassurance for the pet parent, worldwide and throughout the whole life of the pet.

Good growth while profitability is affected by marketing initiatives

Summary of the period

Numbers in parentheses refer to outcome of the corresponding period of the previous year.

Fourth quarter: October 1st - December 31st, 2025

- Net revenue amounted to **682.3 MSEK** (661.3 MSEK), corresponding to an increase of 3% (5%)
- Organic, currency-adjusted growth amounted to **11%** (4%)
- Operational EBITDA amounted to **108.6 MSEK** (145.3 MSEK), corresponding to a decrease of -25%, and an EBITDA-margin of **15.9%** (22.0%)
- Operational EBITA amounted to **81.3 MSEK** (123.7 MSEK), corresponding to a decrease of -34%, and an EBITA-margin of **11.9%** (18.7%)
- Profit after tax amounted to **16.4 MSEK** (23.8 MSEK)
- Earnings per share calculated on **159,840,958 shares** (158,862,839 shares) amounted to **0.10 SEK** (0.15 SEK)
- Cash flow from operating activities amounted to **44.7 MSEK** (81.7 MSEK)
- As of December 31st, 2025, cash amounted to **103.0 MSEK** (186.8 MSEK)

Full year: January 1st - December 31st, 2025

- Net revenue amounted to **2,683.1 MSEK** (2,530.2 MSEK), corresponding to an increase of 6% (9%)
- Organic, currency-adjusted growth amounted to **9%** (9%)
- Operational EBITDA amounted to **511.0 MSEK** (560.7 MSEK), corresponding to a decrease of -9%, and an EBITDA-margin of **19.0%** (22.2%). The operational adjustments totaling 59.7 MSEK include mainly a non-cash flow-impacted evaluation of acquisition stock to fair value, as well as M&A costs, costs for the implementation of an ERP system and costs that relate to prior years
- Operational EBITA amounted to **424.4 MSEK** (478.0 MSEK), corresponding to a decrease of -11% and an EBITA-margin of **15.8%** (18.9%). The operational adjustments of total 2.9 MSEK refers to costs that relate to prior years
- Profit after tax amounted to **55.5 MSEK** (98.9 MSEK)
- Earnings per share calculated on **159,599,778 shares** (158,786,637 shares) amounted to **0.35 SEK** (0.62 SEK)
- Cash flow from operating activities amounted to **326.8 MSEK** (359.1 MSEK)
- The board proposes a dividend of **0.28 SEK** (0.25 SEK) per share

Significant events during the fourth quarter

Swedencare announces new financial targets for the next five years to reflect the current market situation, growth ambitions and commitment to shareholder value.

Significant events after the fourth quarter

There are no significant events after the end of the fourth quarter to comment on.

Words from the CEO

The fourth quarter's net revenue of 682 MSEK represented an increase of 3% compared to Q4 2024 and was negatively affected by the strengthening of the Swedish krona over the year. The currency impact on our profit is limited since we almost exclusively have costs and revenues in the same currency across our group companies around the world. Our operational EBITDA margin was 16% and amounted to 109 MSEK, negatively affected by a number of factors of either one-off or temporary nature. Despite weaker profitability than expected, our operating cash flow was positive at 45 MSEK, and we continued to amortize our debt by 65 MSEK during the quarter.

Full year 2025

The full year net revenue of 2,683 MSEK represented an increase of 6% compared to 2024, and was also negatively affected by the stronger krona. Our operational EBITDA margin was 19% and amounted to 511 MSEK. Despite weaker profitability than expected, our operating cash flow was positive at 327 MSEK, and during 2025 we amortized a total of 233 MSEK.

Our organic growth amounted to 11% for the quarter and 9% for the year. Both quarterly and annual figures show stronger growth than the market (6-7%), but our ambition is to achieve double-digit growth also on a full-year basis.

Profitability during the quarter

As we announced in our press release on January 30th, profitability during the quarter was weaker than I had expected, primarily due to four reasons:

- Higher marketing costs on Amazon associated with longer than expected transition and control of NaturVet Amazon account
- ERP implementation at NaturVet, which caused operational interruptions including reduced execution speed, downtime and delayed shipments
- Elevated marketing investments to:
    - Build up pull and awareness for new Big Box channel, including targeted campaigns as well as a low-margin display campaign rolled out in 2,000 Walmart stores (1,400 existing + 600 new)
    - Strengthen partner relationships and support the important rebranding initiatives across key channels
- Inventory write offs

I am highly dissatisfied that we could not manage the profitability better together with the double digit and expected growth. The ERP transition and this quarter's inventory write-offs are not recurring. The higher marketing costs were expected, but they should be directly aligned with sales increases – something that unfortunately did not materialize during the quarter. This resulted in a too-high share of marketing spend to support our Big Box launches. We have seen that our investments have given the desired result with the sales in Walmart stores almost doubled in January compared to December and I expect that it will generate a more normalized margin during the current year. Regarding Amazon, it has been difficult to assess the development of moving the NaturVet account in-house. We have taken stronger measures to eliminate third-party sellers of our brand on Amazon, which should lead to improved profitability on Amazon quarter by quarter going forward.

The only larger acquisition of the year, Summit, has developed well and has contributed to a strong increase in the Pharma product group, with a good profitability. Across all markets, underlying consumer demand remains healthy and stable. The trend we have seen, where online grows faster than other channels, continues. North America and Europe had an organic growth of 22% respectively 10%. The production segment decreased with -16%, driven by continued low demand for liquid dermatology products, postponement of Pharma projects to 2026 and that we have increased our internal volumes that do not contribute at the group level.

Forward looking

Swedencare has always grown with good profitability and strong cash flow, which has enabled regular dividend payouts. Against this background, and with a stable balance sheet despite significant investments and initiatives, the Board proposes a dividend of 0.28 SEK per share for decision on the Annual General Meeting this spring.

Over the past two years, we have focused on laying the foundation for stronger future performance. In 2026, we will have completed the Amazon transition for NaturVet and Europe, giving us full control over marketing and pricing. We will also expand our collaborations within the veterinary sector in both Europe and North America, launch several clinically proven products across multiple brands, significantly grow our CDMO Pharma business, and normalize margins in the Big Box channel.

Overall, our strengthened presence in the Big Box channel improves Swedencare's long-term growth profile and forms an important building block for achieving our updated financial targets, which are presented in detail in the report on page 14-15. In addition, we have already implemented several organizational and strategic initiatives focused on profitability improvements.

I would like to conclude by thanking the entire organization for their efforts during the year. We are all focused on gradually moving toward the new financial goals.

Håkan Lagerberg
Malmö February 12th, 2026

Record Online Growth Fueled by key Brands in North America

We delivered robust double-digit growth in North American online channels throughout 2025. This was driven by strong performance from the Pet MD team, which handles online sales in North America of our internal brands including NaturVet®, ProDen PlaqueOff®, Riley's®, Pack Approved™, Rx Vitamins®, and Pet MD® on major e-commerce platforms such as Amazon and Chewy.

Targeted investments in digital marketing, social channels, and influencer partnerships significantly increased visibility and sales, with NaturVet® achieving record volumes, Riley's® and Pack Approved™ gaining significant traction in the treat segment, and Rx Vitamins® and Pet MD® strengthening positions in specialized supplements and dermatology, respectively.

A key strategic achievement was internalization of NaturVet's Amazon account in Q2 2025, transitioning to in-house from third-party management. This move will during 2026, besides from recognition of top-line revenue, give us greater control over branding, pricing, promotions, and enhanced consumer visibility. Even if the transition period was longer than anticipated and led to elevated marketing costs, the overall effect has been positive, and will contribute to accelerated online growth and higher profitability for the brand going forward.

ProDen PlaqueOff® maintains its position as Swedencare's fastest-growing brand in 2025, with particularly strong performance in the online channel. Key products including Powder, Dental Bones, and Soft Chews drove substantial sales increases on platforms such as Amazon and Chewy, supported by growing consumer demand for effective, natural oral health solutions and targeted digital campaigns that boosted awareness and repeat purchases. ProDen PlaqueOff® continues to outperform market average growth rates, a trend expected to continue.

We are well positioned for continued momentum into 2026 with planned product launches and further digital optimizations.

Focus areas:

- Increased control of the NaturVet brand
- Continued digital marketing and investment for NaturVet®, ProDen PlaqueOff®, Riley's®, Pack Approved™, Rx Vitamins®, and Pet MD®
- New product launches optimized for online channels
- Strengthened partnerships with leading online retailers

Brian Nugent
Chief Commercial Officer
Swedencare North America

Q4 KPI's Swedencare Group

Net revenue
682.3 MSEK

Change in net revenue
3%

Organic growth
11%

Operational gross margin
56.8%

Operational EBITDA
108.6 MSEK

Margin
15.9 %

Net debt/Proforma R12 operational EBITDA
2.9

Operational cash flow
44.7 MSEK

Cash
103.0 MSEK

Development 2020 - 2025

Full year history of net revenue and EBITDA (MSEK)



Quarterly history of net revenue and EBITDA (MSEK)



Net revenue EBITDA Operational EBITDA

Additional KPI's and definitions can be found on page 31-33.

Comments – Financial development

Q4 2025

Net revenue

Net revenue amounted to 682.3 MSEK (661.3 MSEK) which corresponds to an increase of 3% compared to the corresponding period last year. The growth is divided into 11% organic growth, 4% acquired growth and -12% negative currency impact. The acquired growth refers to Summit, which was acquired in April 2025. The currency impact is primarily related to the USD, the Group's most important currency, as well as the EURO and GBP which all weakened further quarter by quarter during 2025.

The North American segment has shown the highest organic growth of 22% for the quarter. The European segment has shown an organic growth of 10% and the production segment has a negative organic growth of -16%.

Full year 2025

Net revenue

For the full year 2025 the net revenue for the Group amounted to 2,683.1 MSEK (2,530.2 MSEK) which corresponds to an increase of 6% compared to last year. The growth is divided into 9% organic growth, -7% currency impact and 4% acquired growth from Summit and Medvant.

For the full year 2025 the European segment has shown the highest organic growth of 14%. The North American segment has shown an organic growth of 12% and the production segment have a negative organic growth of -2%.

Total net revenue





Q4 2025

Segment distribution

North American segment – 60% of total net revenue

The net revenue of the companies belonging to the North American segment amounted to 409.9 MSEK (384.6 MSEK), an increase of 7% compared to the corresponding period last year. The growth is divided into 22% organic growth and -15% currency impact affected by the weaker USD against the SEK. The growth is primarily driven by sales of the NaturVet® brand and ProDen PlaqueOff®, as well as the delivery of significant private label orders during the quarter. It has also been a strong quarter for the Treats product category within the segment.

The North American segment accounts for 60% of the Group's total net sales, compared to 58% during the corresponding period last year.

Full year 2025

Segment distribution

North American segment – 61% of total net revenue

The net revenue in the companies belonging to the North American segment amounted to 1,635.0 MSEK (1,566.1 MSEK), an increase of 4% compared to last year. The growth is divided into 12% organic growth, -8% currency impact and acquired growth is rounded down to 0%. The growth has had a positive impact for the second half year since sales of the NaturVet® brand on Amazon have been managed in-house since April 23rd this year. However, in the first months of the year, sales were temporarily negatively impacted by the transition of moving the NaturVet® Amazon account in-house. During the year, NaturVet® was also launched on Walmart, a part of a new sales channel for the Group, Big Box/FDMC, which further supported growth. Growth for the year was also driven by ProDen PlaqueOff® and the Treats product category, which, although from low levels, showed strong growth in the North American segment.

For the full year 2025 the segment represents 61% of the total revenue of the Group, compared to 62% last year affected by stronger growth and acquisitions within other segment.

North American segment – 60% of total net revenue





Q4 2025

Segment distribution - cont.

European segment – 23% of total net revenue

For the European segment net revenue amounted to 160.0 MSEK (126.8 MSEK), an increase of 26% compared to the corresponding period last year. The growth is divided into 10% organic growth, -6% currency impact and acquired growth amounts to 22%. Acquired growth refers to Summit who contributed to the net revenue with 28.0 MSEK during the quarter. The organic growth in the segment is primarily linked to the UK companies, and the Amazon sales which is increasing quarter by quarter. Another contributing factor is the strong growth in the product category Dental within the segment.

The European segment has increased their share of net revenue compared to the corresponding period last year with four percentage points to 23% (19%). This is due to the acquisition of Summit, which was completed in the second quarter, as well as the strong growth.

Full year 2025

Segment distribution - cont.

European segment – 22% of total net revenue

For the European segment net revenue amounted to 579.8 MSEK (450.2 MSEK) an increase of 29% compared to last year. The growth is divided into 14% organic growth, -3% currency impact and acquired growth amounts to 18%. Summit accounts for the acquired growth, and in terms of organic growth, the UK companies have shown the strongest growth during the year, with Amazon UK leading the way. The product category Dental has shown strong growth in Europe, and in addition to ProDen PlaqueOff®, our veterinary-focused brand Restomyl® is also expanding rapidly across several markets. The Nordics is a market where we have carried out dedicated digital initiatives during the year, which have delivered strong results and, in 2025, led to record-breaking sales quarter after quarter.

This year´s acquisition and growth contributes to the European segment´s share of net revenue increases compared to the corresponding period last year to 22% (18%).

European segment – 23% of total net revenue





Q4 2025

Segment distribution - cont.

Production segment – 17% of total net revenue

Net revenue in the production segment amounted to 112.4 MSEK (149.9 MSEK), a decrease of -25% compared to the corresponding period last year. The growth is divided into -16% organic growth and -9% currency impact. Delays in Pharma projects, as well as a cautious veterinary market for contract manufacturing, are contributing to a decline in the segment.

The internal revenue for the segment has increased with 15% to 45.2 MSEK (39.3 MSEK). Moving more production in-house supports other segments but effect the production segments organic growth negatively since it is eliminated on Group level. The production segment's share of net revenue has decreased compared to the corresponding period last year and represents 17% (23%) of the Group's total net revenue.

Full year 2025

Segment distribution - cont.

Production segment – 17% of total net revenue

Net revenue in the production segment amounted to 468.3 MSEK (513.8 MSEK), a decrease of -9% compared to last year. The growth is divided into -2% organic growth and -7% currency impact. The segment's negative organic growth is due to postponement of significant Pharma projects from the first half of the year to 2026, as well as a cautious veterinary channel.

The internal revenue for the segment has increased with 12% to 181.3 MSEK (162.2 MSEK. Moving more production in-house supports other segments but effect the production segments organic growth negatively since it is eliminated on Group level. For the full year the segment represents 17% (20%) of the Group's total net revenue.

Production segment – 17% of total net revenue





Q4 2025

Product and brand distribution

All amounts and product and brand distribution graphs on this page are not adjusted for currency or acquisitions.

Product group Nutraceuticals shows growth of 3%, and an organic growth of 16%, and continues to represent the Groups largest product category with 47% (47%) of the Group's total net revenue. The growth in the quarter is primarily driven by increased private label sales.

Topicals/Dermatology has decreased with -21% and a negative organic growth of -11% compared to the corresponding period last year which is due to reduced contract manufacturing in the manufacturing segment. The product category represent 17% (23%) of the Group's total net revenue for the quarter.

The Dental product group, which in addition to ProDen PlaqueOff®, also include a few other dental products such as toothpaste (Restomyl®) and dental wipes, has shown growth of 13% of which 23% is organic. The product group continues to increase its share of the Groups total net revenue which during the quarter amounts to 19% (18%). The main contributors to the increase are ProDen PlaqueOff® Powder and Dental Bones as well as Restomyl® that show strong growth.

Sales of Pharma (contract development and manufacturing) have increased 59% of which negative -4% is organic. The growth is acquired as the revenue from Summit falls within the category.

The product group Others has decreased -5% but showed an 12% organic growth and represents 4% (5%) of the Group´s net revenue in the quarter.

The Treats product group continues to grow quarter after quarter and demonstrates, from low levels, a growth of 73% where as 97% is organic and represents 3% (2%) of the Group's total net revenue. The growth is primarily driven by the Pack Approved™ brand.

Full year 2025

Product distribution

Nutraceuticals represents 46% (49%) of the total net revenue and is the groups largest product category. It has shown a decrease in growth of -1% but a positive organic growth of 5% compared to last year.

Topicals/Dermatology has shown negative growth of - 5% but a positive organic growth of 2% and represents 20% (23%) of the Group’s net revenue. The low growth is primarily explained by weaker demand in the North American manufacturing segment during the fourth quarter.

The product group Dental product continues to show strong growth and increase by 23% where as 30% is organic compared to last year. The product group represents 19% (16%) of the Group’s total net revenue. Several subcategories within Dental are demonstrating strong growth, PlaqueOff® Dental Bones, ProDen PlaqueOff® Powder, and Restomyl®, a veterinary-focused dental brand, have all shown solid growth during the year.

The Pharma product group has increased by 52% compared to the previous year, which is due to the fact that all acquired revenue from Summit is categorized as Pharma. The organic growth is negative and amounts to -8%. The product group represents 7% (5%) of the Group’s net revenue.

The product group Other increased by 5% where as 12% is organic and accounts for 4% (5%) of the Group’s net revenue.

The Treats product group shows an increase of 67% where as 79% is organic and represents 3% (2%) of the Group’s net revenue. The growth is primarily driven by increased sales of the Pack Approved™ brand.

Swedencare has, through the acquisitions, built a broad product portfolio with several strong brands.

During Q4 2025 net revenue were distributed by product category as shown in the graphic.



During Q4 2025 net revenue were distributed by brand as shown in the graphic.



Q4 2025

Profit

The gross margin, both reported and operational, amounted for the fourth quarter to 56.8% compared to 58.0% respectively 58.5% the corresponding period previous year. The lower margin in the quarter is mainly due to increased inventory write offs and a low-margin display campaign rolled out in 2,000 Walmart stores. Adjusted for the total effect of 1.5 percentage points, the gross margin would have been in line with the corresponding period last year and the full year 2025. Also, the implementation of Naturvet's new ERP system which caused operational interruptions including reduced execution speed, downtime, increased freight costs and delayed shipments had a negative impact.

The external costs amounts to 176.3 MSEK (149.6 MSEK). Non-operational one-off costs of 1.0 MSEK (3.1 MSEK) is related to implementation costs for a new ERP system. Adjusted for this, external costs amount to 175.3 MSEK, corresponding to 26% of total net revenue, which is two percentage points higher than previous quarters. During the quarter, elevated marketing investments have been done in connection with Big Box/FDMC-launch and higher costs for campaigns connected to Black Week. With the increasing Amazon sales, related marketing costs linked to online sales are also rising, along with their share of total external costs. Personnel costs amounted to 15% of net revenue which is in line with full year 2025.

The operational operating profit before amortization of intangible assets (EBITA) amounted to 81.3 MSEK (123.7 MSEK), corresponding to an operational EBITA margin of 11.9% (18.7%). Of the 27.3 MSEK (21.6 MSEK) in depreciation of tangible assets for the quarter, 11.0 MSEK (10.1 MSEK) is attributable to IFRS16 (leased assets).

Exchange rate variations impacted the period's profit with an exchange rate gain of 3.7 MSEK (1.2 MSEK). During the quarter, the interest expenses on loans taken in connection with the acquisitions amounted to 12.1 MSEK (14.7 MSEK). The lower interest expenses are due continued lower average interest rates.

The net income for the quarter amounted to 16.4 MSEK (23.8 MSEK) corresponding to a net income margin of 2.4% (3.6%).

Earnings per share during the fourth quarter 2025 amounted to 0.10 SEK (0.15 SEK) calculated on a weighted average number of shares, 159,840,958 (158,862,839) as of December 31st, 2025.

Full year 2025

Profit

The gross margin amounted to 56.3% (57.3%). Adjusted for non-operational revaluation of Summits acquisition inventory to fair value of 47.9 MSEK (12.9 MSEK) the operational gross margin amounts to 58.1% (57.9%).

The external costs amounts to 646.6 MSEK (524.0 MSEK). Adjusted for non-operational one-off costs of 10.8 MSEK (4.7 MSEK), primarily attributable to acquisition costs and implementation costs for a new ERP system, which corresponds to 24% of total net revenue. Personnel costs amounted to 16% of net revenue, same share as last year. Personnel costs related to stock option program under IFRS2 amounted to 1.4 MSEK for the year.

The operational operating profit before amortization of intangible assets (EBITA) amounted to 424.4 MSEK (478.0 MSEK), corresponding to an operational EBITA margin of 15.8% (18.9%). Of the 89.5 MSEK (82.7 MSEK) in depreciation of tangible assets for the year, 40.6 MSEK (39.6 MSEK) is attributable to IFRS16 (leased assets).

Exchange rate variations impacted the profit of the year with an exchange rate gain of 6.3 MSEK (5.4 MSEK). During year the interest expenses on loans taken in connection with the acquisitions amounted to 51.8 MSEK (71.6 MSEK).

The net income for the year amounted to 55.5 MSEK (98.9 MSEK) corresponding to a net income margin of 2.1% (3.9%).

Earnings per share during 2025 amounted to 0.35 SEK (0.62 SEK) calculated on a weighted average number of shares, 159,599,778 (158,786,637) as of December 31st, 2025.

Cash flow

Cash flow from operating activities amounted to 326.8 MSEK (359.1 MSEK). During 2025 the change of working capital was -30.5 MSEK (-76.2 MSEK), primarily explained by an increased inventory value and an increase of accounts receivable.

During the first quarter of the year, Swedencare completed an asset acquisition of Pack Approved™ where the total purchase price paid out during 2025 amounts to 43.6 MSEK. During the second quarter, Swedencare acquired Summit for 389.3 MSEK. Of the total purchase price, 349.6 MSEK was paid in cash and 39.7 MSEK through a non-cash issue. The asset acquisition of NaturVet's Amazon account amounted to 78.5 MSEK and was financed by utilizing the company's existing RCF. During the third quarter, a minority acquisition in Viyo was completed for a purchase consideration of 8.5 MSEK.

Investments in tangible and intangible fixed assets amounted to 51.2 MSEK (45.1 MSEK) for the full year, which corresponds to 2% (2%) of net revenue.

Q4 2025

Cash flow

Cash flow from operating activities amounted to 44.7 MSEK (81.7 MSEK). During the quarter, the change of working capital was -4.3 MSEK (-20.1 MSEK) which primarily can be explained by increased accounts receivable, decreased deferred revenue and other liabilities.

Investments in tangible and intangible fixed assets amounted to 13.9 MSEK (13.8 MSEK) during the fourth quarter, which corresponds to 2% (2%) of net revenue.

During the quarter, 65.0 MSEK was amortized on the long-term loan. Cash flow amounted to -44.8 MSEK (-16.8 MSEK).

Full year 2025

Cash flow – cont.

During the year the dividend of 2024 was paid, which affected the cash flow with 40.0 MSEK, equivalent with 0.25 SEK per share.

During the year, the Group's long-term loans to credit institutions have been refinanced. Interest-bearing liabilities increased by 450 MSEK in connection with acquisitions, while amortizations amounted to 233 MSEK. During 2025, cash flow amounted to -66.8 MSEK (-66.9 MSEK).

Other financial comment

Financial position

Swedencare's equity as of December 31st, 2025 amounted to 6,665.0 MSEK (8,032.1 MSEK), of which 1.6 MSEK (1.6 MSEK) is restricted equity. Swedencare's cash and cash equivalents as of December 31st, 2025 amounted to 103.0 MSEK (186.8 MSEK), the Group had by the same date interest bearing short- and long-term debts of 1,804.0 MSEK (1,465.1 MSEK). The group has a cash pool structure for the US companies and has also set up a structure in Europe in 2025, which allows for a lower cash level – cash has decreased with 83.7 MSEK during the year - as well as lower debt position and lower financing costs. Swedencare's net debt, as of December 31st, 2025, amounted to 1,701.0 MSEK (1,278.4 MSEK).

The increase in right-of-use assets for buildings during the quarter is primarily attributable to a new ten-year lease agreement entered into at the end of November for an expansion project in Vetio South, with a right-of-use asset of 143.2 MSEK recognized.

Personnel

Swedencare had as of December 31st, 2025 a total of 613 employees spread over Sweden (21), England (87), Italy (20), France (2), Greece (11), Ireland (26), Spain (5), USA (366) and Canada (75). The gender distribution is 51% women and 49% men. As of December 31st, 2024, Swedencare had a total of 579 employees. The increase during the year is attributable to Summit, the company acquired in Q2, which has a total of 42 employees.

Financing

As of December 31st, 2025, Swedencare's liabilities to credit institutions amounted to 1,460 MSEK. The Group has a term-loan of 800 MSEK and a Revolving Credit Facility (RCF) of 1,000 MSEK, of which the utilized amount was 660 MSEK as of December 31st, 2025. The utilized amount is divided into two draws, maturing at 1-month intervals. The loans are subject to a floating interest rate (STIBOR + margin) linked to net debt. The weighted average interest rate as of December 31st, 2025, was 2.95% (4.13%). The loans extends to June 2028 with the possibility of two extension options of one year at a time, which gives a possible final maturity in June 2030. As of December 31st, 2025 the Group has unused credit facilities of 340 MSEK.

The loans are subject to financial covenants regarding the financial net debt to proforma EBITDA ratio and interest coverage ratio. As of December 31st, 2025, the reported net debt to proforma R12 operational EBITDA ratio, both adjusted for IFRS16, was 2.9 compared to 2.1 as of December 31st, 2024. Swedencare has complied with all covenants set by the bank for all assessments related to borrowing.

New financial targets

The global pet care and health market is experiencing strong, long-term growth, driven by rising pet ownership, increased consumer spending, and a growing focus on preventive health. Swedencare is well positioned to capture this momentum with its premium, science-backed product portfolio in supplements and dental care. Supported by a diversified geographic presence with products sold in ~70 countries through online channels, pet stores, veterinarians, and FDMC, Swedencare's omnichannel footprint enables it to reach engaged pet owners globally.

- **Annual double-digit organic growth**
- **Establish an Op. EBITDA margin above 26% midterm (approx. 23% Op. EBIT margin)**
- **Dividend payout* of 40% of net profit, adjusted for non-operating costs**
- **Net debt/R12 Op. EBITDA (proforma and adjusted for IFRS16) ratio below 2.0****

*Swedencare will propose a dividend that considers the Group's profit as well as its consolidation and investment needs, liquidity, and financial position.
**Subject to flexibility for acquisitions.

The updated financial targets are supported by the long term growth in the market, strategic initiatives and structural key growth drivers across the Group. These are the building stones to enable scalable, profitable growth over time.

Long term market growth

The global pet care market is growing steadily. Industry forecasts expect spending to surpass $500 billion by 2030[1]. Pet health (veterinary care, pharmaceuticals, wellness) is expanding even faster[2]. A larger pet population and higher spending per pet create a robust backdrop for Swedencare's science-backed health product portfolio. This broad market expansion provides a supportive long-term demand environment for Swedencare's portfolio of pet health products.

Pet owners, particularly Millennials and Gen Z, are driving demand for higher-quality, health-oriented products. Key drivers include humanization, premiumization, preventive care, and digital engagement.

- Humanization and demographics: Pets are increasingly treated as family members. U.S. Gen Z pet ownership rose 43.5% in one year, and 70% of Gen Z owners have multiple pets[7].
- Premiumization and quality focus: Owners are trading up in food, treats, and services.
- Preventive health and wellness: Spending is shifting toward prevention, including supplements and wellness products. Over 70% of Millennial and Gen Z pet owners use calming products for their pets[10], supporting demand for preventive categories such as supplements and dental care.
- Digital and omnichannel engagement: E-commerce continues to gain share. U.S. pet e-commerce is projected to reach ~$58.4 billion by 2030, on its way to becoming roughly one-third of all pet consumer spending[11].

Strategic initiatives

Expansion into Big Box retail strengthens Swedencare's channel mix and significantly broadens access to new consumer segments. Big Box, often referred to as the FDMC channel (Food, Drug, Mass & Club), represents a channel opportunity comparable in size to traditional pet specialty retail, making it an important growth lever in the U.S. market.

During the third quarter, Swedencare entered 1,400 Walmart stores and around 1,100 CVS locations, marking one of the Group's largest retail rollouts to date. Importantly, this represents an initial step within a channel that has a substantially larger store footprint, highlighting the long-term expansion potential. In addition, as part of a campaign selection of NaturVet's products is also visible in 600 additional 600 Walmarts stores on end-caps.

By complementing its strong presence in veterinary clinics, pet specialty retail, and online channels, Big Box retail increases visibility, supports higher volumes, and enables scalable growth without diluting product margins. Over time, this expanded channel reach is expected to support both growth and brand awareness across key markets.

Scaling production to support future demand

Continued investments in manufacturing capabilities, including the expansion of Vetio South in the U.S., enhance Swedencare's ability to scale efficiently. Increased production capacity and flexibility strengthen the Group's operational platform and support continued growth across product categories and markets.

Structural key growth drivers

- **Pharma:** Expected to be one of the fastest-growing product groups, supported by a strong pipeline and good visibility from contracted projects. With higher profitability than the Group average, Pharma growth also supports positive margin mix over time.
- **Big Box/FDMC retail:** A channel opportunity comparable in size to traditional pet retail, expanding reach to new consumer segments without diluting margins.
- **Amazon, D2C & other online:** Continued growth in e-commerce, supported by improved channel economics as key markets transition to in-house operations.
- **Product portfolio expansion & innovation:** Ongoing portfolio expansion across core health categories, supported by science-backed development and strong brands.
- **Pricing opportunities:** Selective pricing initiatives remain available, supported by strong brands and limited historical price increases.

Summary and outlook

Supported by a structurally resilient and growing pet health market, updated financial targets, and continued investments in channels and operations, we have a strong platform for long-term, profitable development. By aligning our strategic priorities with enduring market drivers, we are well positioned to continue creating value for customers, partners, and shareholders.

Sources:
1,5: Bloomberg Intelligence (2023). "Global Pet Industry to Grow to $500 Billion by 2030".
2: The Business Research Company, Global Pet Healthcare Market Report (2024)
3,4: American Pet Products Association, 2025 State of the Industry Report

Stock

The ten largest shareholders the table summarizes Swedencare's ownership structure as of December 31st, 2025:

	Number of shares	Ownership
Symrise AG	65,285,601	40.8%
Håkan Svanberg & Co Health Care AB	23,090,775	14.4%
JCC Group Invest Sweden AB (Johan Bergdahl through company)	7,526,755	4.7%
Handelsbanken Fonder	7,230,067	4.5%
Första AP-fonden	7,151,196	4.5%
Mastan AB (Håkan Lagerberg through company)	5,760,166	3.6%
Avanza Pension	3,331,691	2.1%
SEB Fonder	3,219,822	2.0%
Alcur Fonder	2,817,223	1.8%
AMF Pension & Fonder	2,167,371	1.4%
Other	32,260,291	20.2%
Total	159,840,958	100.0%
Free float*	55,550,685	34.8%

Holdings include related parties
**Shares not owned by board members, management, their close related parties, shareholders with more than 10% or which are part of lockup agreement.*

	Number of shares	Share price
31 Dec 2025	159,840,958	38.4
31 Dec 2024	158,862,839	48.2
31 Dec 2023	158,731,900	61.0
31 Dec 2022	158,731,900	30.8

Dividend per share (SEK)



**0,28 by the board proposed dividend to the annual general meeting – not settled*

Op. EBITA per share (SEK)



Operating cashflow per share (SEK)



Financial overview

Consolidated profit and loss

	Oct - Dec 2025	Oct - Dec 2024	Full year 2025	Full year 2024
Net revenue	682.3	661.3	2,683.1	2,530.2
Other revenue	2.4	3.7	11.5	9.7
Total revenue	684.8	664.9	2,694.6	2,539.9
Cost of sales	-294.5	-277.6	-1,173.1	-1,080.4
Other external costs	-176.3	-149.6	-646.6	-524.0
Personnel costs	-104.6	-97.8	-417.4	-390.0
Other costs	-1.1	-0.8	-6.2	-4.6
Operating profit before depreciation (EBITDA)	108.2	139.1	451.3	540.9
Depreciation and write-downs of tangible fixed assets	-27.3	-21.6	-89.5	-82.7
Operating profit before interest, taxes and amortization (EBITA)	80.9	117.5	361.8	458.2
Amortization of intangible fixed assets	-53.4	-59.5	-221.2	-233.2
Operating profit (EBIT)	27.4	58.0	140.6	225.0
Financial income	5.6	1.5	15.6	8.7
Financial costs	-20.6	-17.7	-75.0	-82.3
Results from shares in associated companies	1.0	0.0	1.1	-0.9
Profit after financial costs	13.4	41.8	82.5	150.5
Net income before tax	13.4	41.8	82.5	150.5
Tax on profit	-14.9	-10.2	-60.0	-39.1
Deferred tax	17.9	-7.8	33.0	-12.5
Net income*	16.4	23.8	55.5	98.9
Earnings per share before and after dilution (SEK)	0.10	0.15	0.35	0.62

Consolidated statement of comprehensive income

Net income*	16.4	23.8	55.5	98.9
Exchange difference foreign subs.	-189.2	675.4	-1,423.6	756.0
Total profit*	-172.7	699.3	-1,368.1	855.0

***Ownership without controlling influence does not exist.*

Consolidated balance sheet

	31 Dec 2025	31 Dec 2024
ASSETS		
Non-current assets		
Goodwill	3,905.8	4,336.6
Other intangible assets	3,731.0	4,166.0
Shares in associated companies	10.3	0.6
Buildings and land	125.8	146.7
Right of use according to IFRS - Buildings and land	332.0	208.2
Machinery and other tech assets	132.0	143.8
Right of use according to IFRS - Machinery and other tech assets	7.3	6.4
Tools, furniture, and fixtures	12.4	8.4
Other financial assets	2.0	0.8
Deferred tax asset	147.8	128.4
Total non-current assets	8,406.4	9,145.8
Current assets		
Inventory	492.7	475.9
Accounts receivables	289.0	293.0
Tax receivables	141.3	117.3
Other receivables	11.6	6.2
Prepaid costs and deferred revenue	65.4	91.4
Cash	103.0	186.8
Total current assets	1,103.1	1,170.6
TOTAL ASSETS	9,509.4	10,316.4

Consolidated balance sheet – cont.

EQUITY AND LIABILITIES	31 Dec 2025	31 Dec 2024
Equity		
Share capital	1.6	1.6
Share premium	6,257.4	6,216.5
Conversion reserves	110.8	1,525.3
Other equity incl. full year profit	295.1	288.7
Total equity	6,665.0	8,032.1
Long term liabilities		
Debt to credit institutions	1,456.3	1,241.9
Other interest-bearing liabilities	295.2	180.0
Deferred tax liability	506.9	455.4
Debts to employees	4.4	5.0
Other long-term liabilities	163.8	5.5
Short term liabilities		
Accounts payable	108.1	112.2
Tax liabilities	157.4	136.2
Other interest-bearing liabilities	52.6	43.2
Other liabilities	26.4	20.0
Deferred costs and prepaid income	73.5	84.8
Total liabilities	2,844.5	2,284.3
TOTAL EQUITY AND LIABILITIES	9,509.4	10,316.4

Consolidated change of equity

	Oct - Dec 2025	Oct - Dec 2024	Full year 2025	Full year 2024
Beginning balance	6,837.1	7,332.9	8,032.1	7,206.8
New share issued / share based compensations	0.5	-	40.9	6.9
Paid dividend	-	-	-40.0	-36.5
Total profit	-172.7	699.3	-1,368.1	855.0
Ending balance	6,665.0	8,032.1	6,665.0	8,032.1

Consolidated cash flow statement

	Oct - Dec 2025	Oct - Dec 2024	Full year 2025	Full year 2024
Operating income before financial costs	27.4	58.0	140.6	225.0
Depreciation	80.7	81.1	310.6	315.9
Non-cash flow items	-8.1	-0.2	21.5	-0.3
Paid interest	-12.6	-15.7	-54.6	-72.2
Paid tax	-38.5	-21.3	-60.9	-33.2
Operating cash flow before change of working capital	49.0	101.9	357.3	435.3
Change in working capital				
Change in inventory	15.3	7.4	-22.5	-25.2
Change of accounts receivable	-9.4	-17.8	-29.2	-39.3
Change of other receivables	8.1	-17.9	8.9	-27.8
Change of accounts payable	-5.8	6.1	18.6	16.3
Change in current liabilities	-12.5	2.0	-6.3	-0.2
Operating cash flow	44.7	81.7	326.8	359.1
Investment activities				
Acquisitions	-	-	-480.2	-80.7
Purchases of intangible assets	-0.7	-2.9	-3.8	-30.5
Purchases of buildings	-1.9	-5.8	-4.8	-11.2
Purchases of machines	-10.6	-4.2	-37.5	-25.7
Purchases of tools, furniture, and fixtures	-0.7	-0.9	-5.1	-3.9
Cash flow from investment activities	-13.9	-13.8	-531.4	-151.9
Financial activities				
Paid dividend	-	-	-40.0	-36.5
Loan	-	-	2,050.0	-
Amortization on interest-bearing loan	-65.0	-75.0	-1,833.0	-200.0
Amortization on lease	-10.5	-9.7	-39.2	-37.6
Cash flow from financial activities	-75.5	-84.7	137.8	-274.2
Cash flow for the period	-44.8	-16.8	-66.8	-66.9
Cash balance at beginning of period	145.1	193.1	186.8	237.3
Exchange difference in cash	2.7	10.4	-17.0	16.4
Cash balance at end of period	103.0	186.8	103.0	186.8

Parent company profit and loss

	Oct - Dec 2025	Oct - Dec 2024	Full year 2025	Full year 2024
Net revenue	19.4	23.6	84.0	84.1
Other revenue	8.2	9.0	10.3	11.4
Total revenue	27.7	32.6	94.2	95.4
Cost of sales	-7.3	-7.4	-25.9	-25.1
Other external costs	-6.5	-6.9	-28.5	-22.9
Personnel costs	-7.0	-7.3	-32.5	-30.5
Other costs	-0.4	-0.3	-2.8	-2.6
Operating profit before depreciation (EBITDA)	6.5	10.7	4.5	14.5
Depreciation and write-downs of tangible fixed assets	0.0	0.0	-0.1	0.0
Operating profit before interest, taxes and amortization (EBITA)	6.5	10.7	4.5	14.4
Amortization of intangible fixed assets	-0.1	-0.3	-0.6	-1.1
Operating profit (EBIT)	6.3	10.4	3.9	13.4
Financial income	1.8	1.3	4.7	3.9
Financial costs	-13.8	-15.8	-47.0	-71.6
Results from shares in associated companies	63.9	71.9	245.9	376.1
Profit after financial costs	58.2	67.8	207.4	321.8
Year-end adjustments	2.3	2.4	2.3	2.4
Net income before tax	60.5	70.2	209.7	324.2
Tax on profit	-1.9	-2.0	-2.5	-3.3
Net income	58.5	68.2	207.1	321.0

Parent company balance sheet

ASSETS	31 Dec 2025	31 Dec 2024
Non-current assets		
Trademarks and other intangible assets	0.7	1.2
Tools, furniture and fixtures	0.1	0.1
Shares in subsidiaries	8,927.2	8,230.9
Shares in associated companies	10.1	1.6
Total non-current assets	8,938.1	8,233.8
Current assets		
Inventory	9.7	8.0
Accounts receivables	3.3	10.2
Intercompany receivables	105.8	53.6
Other receivables	0.4	0.3
Prepaid costs and deferred revenue	2.2	2.9
Cash	25.1	70.0
Total current assets	146.6	145.0
TOTAL ASSETS	9,084.7	8,378.8

EQUITY AND LIABILITIES	31 Dec 2025	31 Dec 2024
Equity		
Share capital	1.6	1.6
Share premium	6,257.4	6,216.5
Retained earnings including net income	998.2	831.0
Total equity	7,257.2	7,049.1
Long term liabilities		
Debt to credit institutions	1,456.3	1,241.9
Other liabilities	186.3	-
Short term liabilities		
Accounts payable	1.8	3.6
Intercompany payables	172.5	67.4
Tax liabilities	2.2	2.7
Other liabilities	1.6	1.4
Deferred costs and prepaid income	6.9	12.7
Total liabilities	1,827.5	1,329.7
TOTAL EQUITY AND LIABILITIES	9,084.7	8,378.8

Revenue breakdown per segment – Q4 2025

Geographic market	North America		Europe		Production		Group		Change %
	2025	2024	2025	2024	2025	2024	2025	2024	
North America	405.6	378.0	0.7	-0.9	72.9	105.8	479.1	482.9	-1%
Europe	0.6	1.1	154.3	115.8	38.9	44.0	193.9	161.0	20%
Rest of the world	3.7	5.4	5.0	11.9	0.7	0.1	9.4	17.4	-46%
Total	409.9	384.6	160.0	126.8	112.4	149.9	682.3	661.3	3%

Product areas	North America		Europe		Production		Group		Change %
	2025	2024	2025	2024	2025	2024	2025	2024	
Topicals/Dermatology	62.0	67.6	11.6	15.9	45.7	67.4	119.4	150.9	-21%
Dental	68.8	65.9	54.3	47.8	9.9	4.4	133.0	118.1	13%
Treats	20.6	11.9	-	0.0	-	0.0	20.6	11.9	73%
Nutraceuticals	229.5	209.9	64.6	61.1	25.4	40.3	319.5	311.3	3%
Pharma	-	-	28.0	-	32.2	37.8	60.2	37.8	59%
Other	29.1	29.3	1.5	2.0	-0.8	0.1	29.7	31.3	-5%
Total	409.9	384.6	160.0	126.8	112.4	149.9	682.3	661.3	3%

Time of revenue recognition	North America		Europe		Production		Group		Change %
	2025	2024	2025	2024	2025	2024	2025	2024	
The performance commitment is met over time	-	-	-	-	73.5	105.7	73.5	105.7	-30%
The performance commitment is met a certain time	413.8	395.8	160.0	126.8	38.9	44.2	608.8	555.6	10%
Total	409.9	384.6	160.0	126.8	112.4	149.9	682.3	661.3	3%

Revenue breakdown per segment – Full Year 2025

Geographic market	North America		Europe		Production		Group		Change %
	2025	2024	2025	2024	2025	2024	2025	2024	
North America	1614.6	1542.1	0.7	-0.9	319.1	377.1	1940.5	1918.3	1%
Europe	3.9	3.6	544.0	415.3	148.2	136.5	696.1	555.4	25%
Rest of the world	16.5	20.4	35.1	35.8	1.0	0.3	52.6	56.5	-7%
Total	1,635.0	1,566.2	579.8	450.2	468.3	513.8	2,683.1	2,530.2	6%

Product areas	North America		Europe		Production		Group		Change %
	2025	2024	2025	2024	2025	2024	2025	2024	
Topicals/Dermatology	262.0	286.0	55.4	57.2	232.6	234.8	549.9	578.0	-5%
Dental	255.0	227.0	208.3	162.5	36.9	16.8	500.1	406.3	23%
Treats	73.8	44.2	0.0	0.1	-	-	73.8	44.2	67%
Nutraceuticals	911.3	884.7	228.4	221.7	98.2	142.6	1,238.0	1,249.0	-1%
Pharma	-	-	81.4	-	99.7	119.4	181.1	119.4	52%
Other	132.9	124.3	6.4	8.7	0.9	0.3	140.2	133.3	5%
Total	1,635.0	1,566.2	579.8	450.2	468.3	513.8	2,683.1	2,530.2	6%

Time of revenue recognition	North America		Europe		Production		Group		Change %
	2025	2024	2025	2024	2025	2024	2025	2024	
The performance commitment is met over time	-	-	-	-	320.9	376.8	320.9	376.8	-15%
The performance commitment is met a certain time	1,635.0	1,566.2	579.8	450.2	147.5	137.1	2,362.3	2,153.5	10%
Total	1,635.0	1,566.2	579.8	450.2	468.3	513.8	2,683.1	2,530.2	6%

Note 1 Operating segment the Group – Q4 2025

An operating segment is a part of the Group that conducts activities from which it can generate revenues and incur expenses, with its operating results regularly reviewed by the company's highest executive decision-maker and for which separate financial information is available. The Group's operations are reported by geographical area (North America, Europe) as well as by manufacturing units. The operating segments are reported in a manner consistent with the internal reporting provided to the highest executive decision-maker, who is responsible for resource allocation and monitoring the results of the operating segments. In the Swedencare Group, this function has been identified as the CEO and CFO. The CEO and CFO use the same operating segments in their reporting of the Group's financial performance to the board, confirming that the external and internal reporting are aligned.

The North American operating segment includes seven sales companies in North America.
The European operating segment includes nine sales companies in Europe.
The Production operating segment includes Vetio (Canada, UK and USA), Swedencare Tillverka (USA), and Swedencare Ireland (Ireland).

	North America		Europe		Production		Group-wide functions		Group	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Net revenue external	409.9	384.6	160.0	126.8	112.4	149.9	0.0	0.0	682.3	661.3
Net revenue internal, between segments	0.6	1.1	13.4	11.4	45.2	39.3	-59.2	-51.8	-	-
Net sales	410.5	385.6	173.4	138.2	157.7	189.2	-59.2	-51.8	682.3	661.3
Other revenue external	1.7	1.8	6.6	7.9	0.3	0.1	-6.3	-6.3	2.4	3.7
Total revenue	412.2	387.4	179.9	146.2	158.0	189.3	-65.4	-58.0	684.8	664.9
Cost of sales	-192.8	-177.7	-58.7	-50.0	-96.1	-106.5	53.1	56.6	-294.5	-277.6
Other external costs	-122.0	-105.2	-32.7	-26.5	-15.4	-18.1	-6.2	0.2	-176.3	-149.6
Personnel costs	-56.2	-50.6	-18.0	-13.0	-24.8	-27.5	-5.6	-6.7	-104.6	-97.8
Other costs	0.0	0.0	-1.1	-0.6	0.0	-0.2	0.0	0.0	-1.1	-0.8
EBITDA	41.3	53.9	69.4	56.1	21.7	37.1	-24.1	-7.9	108.2	139.1
Internal management fee	-4.0	-	0.0	-	-2.1	-	6.1	-	-	-
Depreciation and write-downs of tangible fixed assets	-10.2	-11.4	-7.8	-1.7	-9.3	-8.5	0.0	0.0	-27.3	-21.6
EBITA	27.0	42.4	61.6	54.4	10.3	28.6	-18.0	-7.9	80.9	117.5
Amortization of intangible fixed assets	-32.9	-37.0	-6.7	-6.7	-13.8	-15.7	-0.1	-0.1	-53.4	-59.5
EBIT	-5.9	5.4	55.0	47.7	-3.4	12.9	-18.2	-8.1	27.4	58.0
Financial costs	3.6	-0.8	-7.8	-2.2	-1.0	-1.0	-9.8	-12.2	-15.0	-16.2
Results from shares in associated companies	-	0.0	-	-	-	-	1.0	0.0	1.0	0.0
Profit after financial costs	-2.3	4.6	47.1	45.6	-4.4	11.9	-27.0	-20.2	13.4	41.8
Net income before tax	-2.3	4.6	47.1	45.6	-4.4	11.9	-27.0	-20.2	13.4	41.8
Tax on profit	34.0	21.5	-13.1	-8.4	-35.8	-23.3	0.0	0.0	-14.9	-10.2
Deferred tax	-17.0	-16.4	1.2	0.1	46.6	9.8	-12.8	-1.2	17.9	-7.8
Net income	14.7	9.7	35.2	37.2	6.3	-1.7	-39.8	-21.4	16.4	23.8

Note 1 Operating segment the Group – Full year 2025

	North America		Europe		Production		Group-wide functions		Group	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Net revenue external	1,635.0	1,566.2	579.8	450.2	468.3	513.8	-	-	2,683.1	2,530.2
Net revenue internal, between segments	3.0	4.8	44.4	40.2	181.3	162.2	-228.7	-207.1	-	-
Net sales	1,638.0	1,571.0	624.2	490.4	649.6	676.0	-228.7	-207.1	2,683.1	2,530.2
Other revenue external	6.9	3.7	9.5	11.7	1.6	0.7	-6.5	-6.4	11.5	9.7
Total revenue	1,644.8	1,574.6	633.7	502.1	651.2	676.7	-235.1	-213.5	2,694.6	2,539.9
Cost of sales	-738.3	-732.7	-251.9	-166.9	-367.3	-385.2	184.5	204.4	-1,173.1	-1,080.4
Other external costs	-435.9	-362.9	-117.3	-87.4	-62.5	-58.7	-31.0	-15.0	-646.6	-524.0
Personnel costs	-218.2	-210.4	-67.5	-51.4	-101.8	-100.8	-29.9	-27.4	-417.4	-390.0
Other costs	0.0	0.0	-3.4	-3.7	-1.3	-0.8	-1.5	-0.1	-6.2	-4.6
EBITDA	252.4	268.7	193.6	192.7	118.2	131.2	-112.9	-51.6	451.3	540.9
Internal management fee	-4.0	-	-	-	-2.1	-	6.1	-	-	-
Depreciation and write-downs of tangible fixed assets	-42.5	-45.4	-11.4	-5.7	-35.6	-31.6	0.0	0.0	-89.5	-82.7
EBITA	205.9	223.2	182.2	187.0	80.6	99.6	-106.9	-51.6	361.8	458.2
Amortization of intangible fixed assets	-136.7	-144.7	-26.3	-26.4	-57.6	-61.5	-0.6	-0.6	-221.2	-233.2
EBIT	69.2	78.5	155.9	160.5	23.0	38.1	-107.5	-52.2	140.7	225.0
Financial costs	0.6	-4.2	-17.9	-1.7	-2.0	-2.5	-40.1	-65.2	-59.3	-73.6
Results from shares in associated companies	-	-0.5	-	-	-	-	1.1	-0.5	1.1	-0.9
Profit after financial costs	69.8	73.8	138.1	158.9	21.0	35.7	-146.4	-117.9	82.5	150.5
Net income before tax	69.8	73.8	138.1	158.9	21.0	35.7	-146.4	-117.9	82.5	150.5
Tax on profit	33.5	19.5	-46.6	-28.6	-46.8	-30.1	0.0	0.0	-60.0	-39.1
Deferred tax	-39.7	-33.8	18.4	-0.6	57.6	21.3	-3.2	0.6	33.0	-12.5
Net income	63.5	59.6	109.8	129.7	31.8	26.9	-149.6	-117.2	55.5	98.9

Note 2 Acquisitions completed during the year

Swedencare acquires Summit Veterinary Pharmaceuticals Limited, a leader in the UK's thriving Animal Health Specials Market

On April 1st, 2025 Swedencare acquired 100% of the shares in the leading UK-based company, Summit Veterinary Pharmaceuticals Limited ("Summit"). The company provides customized specialty pharmaceuticals for companion animals and had annual revenues of 7.3 MGBP for 2024 calendar year, along with an operational EBITDA of 2.7 MGBP, resulting in an EBITDA margin of 37%.

The initial purchase price is 30 MGBP (389.3 MSEK) along with a two-year earn-out arrangement. The cash consideration include 27 MGBP (349.6 MSEK) drawn from available cash and RCF-credit and an issue-in-kind of 978,119 shares in Swedencare (39.7 MSEK) to the seller upon closing. The share price of 40.6 SEK for Summit is calculated based on the weighted average price of the parent company's shares during the last 20 banking days prior to March 21, 2025, and is based on the average GBP/SEK exchange rate for the same period, which was 13.2372. A condition-based purchase price (earn-out) of a maximum 15 MGBP may be payable if certain conditions are met by April 1st, 2027.

Summit develops, produces, and sells Animal Health Specials exclusively for veterinary professionals in the UK and Hong Kong. With this strategic acquisition, Swedencare has boosted its presence in the rapidly growing Animal Health Specials market. Summit's strong product portfolio, primarily focused on small animals, has recently expanded into the equine sector. Several new products are set to be introduced in the coming years. Summit's customer base includes over 5,500 veterinary clinics across the UK. No part of the recorded goodwill is expected to be deductible for income tax purposes.



Acquisition	**Summit**
Purchase price	
Cash payment for this year's acquisition	349.6
Issue in kind of shares	39.7
Additional purchase price	157.8
Total purchase price	547.1
Payment for acquisitions:	
Payment for this year's acquisition	349.6
Acquired cash and bank balances	0.0
Issuance costs that are deductible items in equity	0.1
Transaction costs that are included in Net income as Other external costs	4.8
Total paid	354.5
Contributions from acquired companies	
Contribution from the time when the controlling influence existed	
Total revenue	81.4
Net income	28.2
Contributions if the acquisitions had been made January 1st, 2025.	
Total revenue	106.5
Net income	32.7

Acquired assets and liabilities	
Intangible assets	392.2
Tangible assets	17.0
Inventory	57.6
Accounts receivable	14.1
Other current receivables	3.7
Cash	0.0
Total acquired net assets	484.6
Accounts payable	-3.3
Deferred tax liability	-112.1
Other current assets	-5.3
Total acquired net liabilities	-120.7
Goodwill	183.2
Total	547.1

Asset acquisitions

Acquisitions of companies can be classified as either business acquisitions or asset acquisitions, and each acquisition requires an individual assessment. According to IFRS, a business must comprise an integrated set of activities and assets, including at least one input and a significant process that together contributes significantly to the ability to generate output (return). If an acquisition does not generate current output but includes an identifiable asset that can generate output in the future, an organized workforce is required for the acquisition to be classified as a business acquisition. If an acquisition is not assessed as a business, it is reported as an asset acquisition.

A concentration test can be voluntarily applied to determine if an acquisition is an asset acquisition. The test implies that if substantially all of the fair value of the acquired gross assets can be attributed to a single asset or a group of similar assets, the acquisition is classified as an asset acquisition.

Acquisition of Amazon account and inventory

During the second quarter of 2025, Swedencare completed an asset acquisition of an established Amazon account and associated inventory from our former partner. The account in question has historically been an important sales channel for several of NaturVet's brands, and the acquisition enables continued growth while maintaining operational stability.

The transition of NaturVet's Amazon sales in-house, originally planned for the end of 2025, was brought forward in order to reduce business risks and ensure sales continuity. The takeover became effective on April 23rd, 2025.

The total purchase price is lower than the expected annual profit increase from the business, meaning the transaction is expected to contribute positively to both revenue and profitability during the current fiscal year. By acquiring an existing Amazon account, the risks typically associated with migrating to a new seller account, such as loss of revenue, increased marketing costs, and temporarily reduced visibility in the platform's algorithms are avoided.

The acquisition strengthens our presence on Amazon and lays the foundation for continued growth within our prioritized product categories.

Pack Approved

During the first quarter of 2025, Swedencare completed an acquisition classified as an asset acquisition — trademark rights to Pack Approved™, a leading brand and supplier of unique, exotic, and sustainable protein-based health treats for pets. The company primarily sells online (Amazon & Chewy) through PetMD, and the Pack Approved brand represents an additional opportunity within our fast-growing Treats category. These products, made with only one or two ingredients, offer unique protein sources and formats that support our sustainability efforts and enable us to increase our market share within this segment. Pet owners are increasingly demanding high-quality and sustainably produced snacks for their animals, and this expansion allows us to leverage our existing sales channels to offer differentiated solutions to a broader range of customers.

The first part of the purchase price amounted to 23.8 MSEK (2.1 MUSD) and impacted cash flow during the first quarter of 2025. The second part of the purchase price, 9.8 MSEK (1.0 MUSD), has been paid in the third quarter of 2025. A conditional earn-out of 10.0 MSEK (1.0 MUSD) has also been paid since conditions were met before February 4th 2027.

Minority Acquisition

During Q3 we have invested in a minority stake in an interesting company and brand, Viyo. Viyo is a Belgian company that offers liquid products designed to strengthen the immune system, support recovery after surgery, and includes an innovation that helps cats with CKD (Chronic Kidney Disease). There is an option for Swedencare to acquire the remaining shares at a predetermined valuation, provided certain milestones are met. Within the Group, the British entity Nutravet will be the first to launch the product range, which is planned to take place during H1 2026. For other markets and available channels, the launch will occur throughout H2 2026-2027.

Note 3 Material risks and uncertainties; the group and the parent company

The board and the managing director guarantee that the year-end report provides a fair overview of the Company's operations, position, and results. When evaluating Swedencare's future development, it is important to consider risk factors in addition to potential revenue and profit growth. Swedencare's operations are affected by several risks that can have an effect on the company's results and financial position to varying extents. For a description of Swedencare's risks, refer to the management report on pages 61-65 and in note 31 in the annual report for 2024. It is deemed that there have been no significant changes in these risks and uncertainty factors as of December 31st, 2025.

Note 4 Accounting principles

This year-end report has been prepared for the Group in accordance with IAS 34, Interim Financial Reporting, and the Swedish Annual Accounts Act, and for the parent company in accordance with the Swedish Annual Accounts Act. Disclosures in accordance with IAS 34 paragraph 16A are provided, in addition to the financial statements and the accompanying notes, also in other parts of the year-end report. All amounts in the report are presented in Swedish kronor (SEK) and rounded to the nearest million, unless otherwise stated.

Note 5 Change in accounting estimates

When preparing the financial reports in accordance with IFRS, estimations, judgments, and assumptions are made that affect the application of accounting principles and the amounts reported for assets, liabilities, revenues, and expenses. These estimations and assumptions are based on historical experience and a number of other factors that under current circumstances appear reasonable. Actual outcomes may differ from these estimations and judgments. The areas that involve a high degree of judgment, are complex, or are areas where assumptions and estimations are of significant importance to the financial reports are disclosed in the latest annual report. There have been no material changes in the preparation of the year-end report.

Note 6 Transactions with related parties

Transactions with related parties occur within the ordinary course of business and are conducted on commercial terms and at market prices. In addition to the usual transactions between group companies and compensations to management and the board of directors, the following transactions with related parties have taken place during the period from January 1st - December 31st, 2025:

- Purchased services from companies controlled by senior executives for an amount of 0.4 MSEK
- Sold products to companies controlled by senior executives for 0.0 MSEK

Note 7 Fair value

Financial liabilities

Swedencare has one financial liability related to contingent consideration in business acquisition, which is valued at fair value through profit and loss statement. The contingent consideration is attributable to the acquisition of Summit and is based on companies' sales until 2027.

The contingent consideration was valued at fair value at the time of acquisition and was revalued at fair value as of December 31st, 2025. The valuation is based on expected future cash flows, which are discounted using the discount rate (WACC). Swedencare's assessment of the fair value of the financial liability related to contingent consideration as of December 31st, 2025, amounts to 163.8 MSEK. The adjustment to fair value is recognized as a financial expense of 4.2 MSEK during the fourth quarter.

Note 8 incentive programs

Swedencare has two ongoing share-based incentive programs. The purpose of these programs is to support the company's long-term development by aligning employee motivation with the interests of the shareholders. For more information about the programs, see page 45 of the 2024 Annual Report and the minutes from the 2025 Annual General Meeting, available on the company's website.

Malmö February 12th, 2026

Håkan Lagerberg CEO	Håkan Svanberg Board Chairman	Johan Bergdahl Board Member	Sara Brandt Board member
Thomas Eklund Board Member	Isabelle Guiller Board Member	Jean-Yves Parisot Board Member	Ulrika Valassi Board Member

Auditor's review

This year-end report has not been reviewed by the company's auditor.

Future reporting schedule

Interim report Q1	Annual meeting 2026	Half year report Q2	Interim report Q3
23/4 2026	23/4 2026	22/7 2026	21/10 2026

The annual reports for 2025 will tentatively be published on April 2nd, 2026 on www.swedencare.com.

Contact

Swedencare AB (publ), Org.nr. 556470-3790
Medeon Science Park
Per Albin Hanssons väg 41
205 12 Malmö

Visit our website www.swedencare.com

Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 0170
E-mail: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 8554
E-mail: jenny.graflind@swedencare.se

Definition of Key Performance Indicators

In this report, Swedencare presents information that the company's management uses to assess the Group's performance. Some of the key figures presented are not defined according to IFRS. The company believes that these measures provide valuable supplementary information to stakeholders and the company's management as they contribute to the evaluation of relevant trends and the company's performance. Since not all companies calculate key figures in the same way, they are not always comparable to measures used by other companies. Therefore, these key figures should not be seen as a substitute for measures defined according to IFRS. ESMA's guidelines on "alternative performance measures" are applied, which means increased disclosure requirements regarding key figures not defined according to IFRS. Below is a reconciliation of the key figures that Swedencare deems relevant according to these guidelines. Margins are calculated as a percentage of net revenue instead of a percentage of total revenue. Therefore, the comparative figures have been adjusted to provide a more accurate picture.

Net revenue
The main revenue of the company

Change of revenue (%)
Net revenue in relation to the previous corresponding period

Gross profit
Sales revenue minus cost of sales

Gross margin (%)
Gross profit as a percentage of net revenue

EBITDA
Operating profit before depreciation

EBITDA-margin (%)
EBITDA as a percentage of net revenue

EBITA
Operating profit before amortization

EBITA-margin (%)
EBITA as a percentage of net revenue

EBIT
Operating profit

EBIT-marginal (%)
EBIT as a percentage of net revenue

Net income margin (%)
Profit after tax as a percentage of net revenue

Solvency (%)
Equity (equity and untaxed reserves minus deduction for deferred tax) calculated as a percentage of total assets.

Interest-bearing net debt
Interest-bearing debt including financial leasing minus cash.

Earnings per share
Profit for the period attributable to the parent company's shareholders in relation to the average number of shares (definition according to IFRS)

Equity per share
Equity in relation to the number of shares at the end of the period

Organic growth
Change in net sales during the current period, excluding acquisitions and exchange rate effects, in relation to the net sales corresponding period of the previous year. The acquisitions are included in organic net sales after a period of twelve months.

Definition of operational Key Performance Indicator

Operational gross profit
Gross profit excluding items affecting comparability. The measure is relevant for showing the group's result generated by activities.

Operational gross margin (%)
Op. Gross profit as a percentage of net revenue

Operational EBITDA
EBITDA excluding items affecting comparability. The measure is relevant for showing the group's results generated by operating activities.

Operational EBITDA-margin (%)
Op. EBITDA as a percentage of net revenue

Operational EBITA
EBITA excluding items affecting comparability. The measure is relevant for showing the group's results generated by operating activities

Operational EBITA-margin (%)
Op. EBITA as a percentage of net revenue

Operational EBIT
EBIT excluding items affecting comparability. The measure is relevant for showing the group's results generated by operating activities

Operational EBIT-margin (%)
Op. EBIT as a percentage of net revenue.

Net debt/Proforma R12 operational EBITDA
Net debt, excluding lease liabilities, in relation to proforma R12 operational EBITDA, adjusted for acquired companies during the relevant period, as if such companies have been acquired on the first day of the period.

Items affecting comparability

Items affecting comparability refer to events and transactions whose profit effects are important to pay attention to when the period's results are compared with previous periods and include items of a one-off nature that are not directly related to the ongoing operations, and which are adjusted due to specific events. Items affecting comparison are a designation for items which excluded shows the group's earnings excluding items which by their nature are not recurring as part of its ongoing operations. In addition, peer comp analysis is facilitated of companies that do not make acquisitions, while analysis and assessment of acquisition objects becomes more clear and transparent then their EBIT contribution coincides with the actual contribution to the group after consolidation. It is also important to note that the effect of the acquisitions is reflected in the group's capital structure and net debt in accordance with accepted accounting rules

Consolidated Key Performance Indicators

	Oct - Dec 2025	Oct - Dec 2024	Full year 2025	Full year 2024
Result measures				
Net revenue	682.3	661.3	2,683.1	2,530.2
Total revenue	684.8	664.9	2,694.6	2,539.9
Change of revenue (%)	3.2%	5.4%	6.0%	8.9%
Gross margin (%)	56.8%	58.0%	56.3%	57.3%
EBITA	80.9	117.5	361.8	458.2
EBITA-margin (%)	11.9%	17.8%	13.5%	18.1%
EBIT	27.4	58.0	140.6	225.0
EBIT-margin (%)	4.0%	8.8%	5.2%	8.9%
Net income	16.4	23.8	55.5	98.9
Net income margin (%)	2.4%	3.6%	2.1%	3.9%
Share data (SEK)				
Outstanding shares at period close	159,840,958	158,862,839	159,840,958	158,862,839
Average outstanding shares	159,840,958	158,862,839	159,599,778	158,786,637
Earnings per share before and after dilution (SEK)*	0.10	0.15	0.35	0.62
Equity per share (SEK)	41.70	50.56	41.70	50.56
Other information				
Cash	103.0	186.8	103.0	186.8
Interest-bearing net debt	1,701.0	1,278.4	1,701.0	1,278.4
Equity	6,665.0	8,032.1	6,665.0	8,032.1
Balance sheet total	9,509.4	10,316.4	9,509.4	10,316.4
Solvency (%)	70.1%	77.9%	70.1%	77.9%

* KPI's defined according to IFRS

Consolidated Operational Key Performance Indicators

	Oct - Dec 2025	Oct - Dec 2024	Full year 2025	Full year 2024
Net revenue	682.3	661.3	2,683.1	2,530.2
Operational gross profit	387.3	386.8	1,557.9	1,464.9
Operational gross margin (%)	56.8%	58.5%	58.1%	57.9%
Revaluation of acquisition stock to fair value	0.5	-3.2	-47.9	-12.9
Other non-operational items affecting comparability	-	-	-	-2.2
Gross profit	387.8	383.6	1,510.0	1,449.7
Gross margin (%)	56.8%	58.0%	56.3%	57.3%
Operational EBITDA	108.6	145.4	511.0	560.7
Operational EBITDA-margin (%)	15.9%	22.0%	19.0%	22.2%
Merger- and acquisition costs	-	-	-6.3	-1.6
Revaluation of acquisition stock to fair value	0.5	-3.2	-47.9	-12.9
Other non-operational items affecting comparability	-1.0	-3.1	-5.5	-5.3
EBITDA	108.2	139.1	451.3	540.9
EBITDA margin (%)	15.9%	21.0%	16.8%	21.4%
Operational EBITA	81.3	123.7	424.4	478.0
Operational EBITA-margin (%)	11.9%	18.7%	15.8%	18.9%
Merger- and acquisition costs	-	-	-6.3	-1.6
Revaluation of acquisition stock to fair value	0.5	-3.2	-47.9	-12.9
Other non-operational items affecting comparability	-1.0	-3.1	-8.4	-5.3
EBITA	80.9	117.5	361.8	458.2
EBITA margin (%)	11.9%	17.8%	13.5%	18.1%
Operational EBIT	80.7	123.3	421.6	476.4
Operational EBIT-margin (%)	11.8%	18.7%	15.7%	18.8%
Merger- and acquisition costs	-	-	-6.3	-1.6
Revaluation of acquisition stock to fair value	0.5	-3.2	-47.9	-12.9
Other non-operational items affecting comparability	-1.0	-3.1	-8.4	-5.3
Amortization of acquisition-related intangible assets	-52.8	-59.1	-218.4	-231.6
EBIT	27.4	58.0	140.7	225.0
EBIT margin (%)	4.0%	8.8%	5.2%	8.9%

SWEDENCARE

Premium Pet Health Care products.

Read more at swedencare.com